Douvir–N is a combination of lamivudine, zidovudine and nevirapine used for the treatment of patients with Human Immunodeficiency Virus. The objective of this study was to investigate the effect of combined administration of Douvir–N and folic acid on the histology and some Biochemical parameters in the liver of Wistar rats. Forty adult albino Wistar rats were randomly divided into four groups of ten animals each. Group A served as control and were administered with 1ml of distilled water, group B animals were administered with 9.29mg/kg body weight of Douvir–N, Group C animals were administered with a combination of 9.29mg/kg of Douvir–N and 0.07mg/kg of folic acid. Animals in group D were administered with 0.07mg/kg of folic acid. Animals were sacrificed after 30 days and dissected. The liver was removed and fixed in 10% buffered formaldehyde, processed and stained using Haematoxylin and Eosin staining method, carcino-embryonic antigen (CEA) and cytokeratin-7 (CK-7) immunochemistry methods. Stained slides were viewed using light microscope. Blood samples from each rat was collected using syringes and needles, The sera were extracted into fresh test tubes and stored in a refrigerator for analysis of aspartate aminotransaminase test (AST), alanine aminotransaminase test (ALT), alkaline phosphotase (ALP). The liver of Wistar rats administered with Douvir–N showed distortions in the liver with moderate dilatation of the sinusoidal spaces and nuclei pyknotic changes, with increased expression of CEA and CK7 in the groups treated with Douvir–N than the control groups. There was a significant increase in ALP in the Douvir–N groups. These changes were ameliorated when Douvir–N was combined with Folic acid. The findings suggest that Douvir–N can distort the cytoarchitecture and Biochemical parameters of the liver which could be ameliorated by co-administration with folic acid. Folic acid should be given as adjuvant drug to patients on Douvir–N therapy.
| Published in | American Journal of BioScience (Volume 3, Issue 6) |
| DOI | 10.11648/j.ajbio.20150306.11 |
| Page(s) | 197-202 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Liver, Douvir–N, Folic Acid, Human Immunodeficiency Virus (HIV), Biochemical Parameters
| [1] | https://www.patientslikeme.com/treatment_evaluations/browse/20908-douvirn-reviews? brand=f. Retrieved on line March 22nd, 2015 |
| [2] | http://www.aidsmeds.com/archive/PIs_1068.shtml. Retrieved online on June 7th 2014. |
| [3] | http://www.globalsources.com/si/AS/Parthweb-Solutions/6008837110868/pdtl/Duovir—N /1116459774.htm. Retrieved on line March 22nd, 2015. |
| [4] | Schambelan, M., Benson, C. and Carr, A. Acquired immune deficiency syndrome. Int. AIDS Soc. USA. Panel, 2002; 9: 30-32. |
| [5] | http://www.indiamart.com/shivroyallifecare/cipla-hiv.html. Retrieved online on March 22nd, 2015. |
| [6] | http://aidsinfo.nih.gov/contentfiles/sideeffectanithivmeds_cbrochure_en.pdf retrieved online on February 11th, 2015. |
| [7] | Sulkowski, M. S., Thomas, D. L., Mehta, S. H., Chaisson, R.E and Moore, D. R. Hepato-toxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology, 2002; 35: 182-189. |
| [8] | Abrescia, N., M. D'Abbraccio, M. Figoni, A. Busto, A. Maddaloni and De Marco, M. Hepatotoxicity of antiretroviral drugs. Curr. Pharm. Des., 2005; 11: 3697-3710. |
| [9] | Verucchi, G. L., Calza, L., Biagetti, C., Attard, L., Costagliola, R., Manfredi, R. et al. Ultrastructural liver mitochondrial abnormalities in HIV/HCV-coinfected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2004; 35: 326–328. |
| [10] | Walker, U. J. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology, 2004; 39: 311-317. |
| [11] | Carr, A., Morey, A., Mallon, P., Williams, D. and Thorburn, D. R Fatal Portal Hypertension, Liver Failure, and Mitochondrial Dysfunction after HIV-1 Nucleoside Analogue-Induced Hepatitis and Lactic Acidaemia. The Lancet, 2001; 357(9266): 1412–1414. |
| [12] | Glenn, J. and Adam, I. Neurologic and Psychiatric Complications of Antiretroviral Agents. AIDS, 2002; 16:1201-1215. |
| [13] | McDowell, M. A., Lacher, D. A and Pfeiffer, C. M. Blood folate levels: the latest NHANES results. NCHS data briefs, 2008; 6:1-8. |
| [14] | Berry, R. S; Li, Z and Erickson, J. D. Prevention of NTD with folic acid in china. US collaborative project for NTD prevention. N. Engl. J. med, 1999; 341: 1485-90. |
| [15] | Botto, L. D; Moore, C. A and Khoury, M. J. Neural tube defects. N. Engl. J. med. 1999; 34:1509-19. |
| [16] | Hobbins, J. C. Diagnosis and management of NTDs today. N. Engl. J. Med. 1991; 324:690-91. |
| [17] | Kim, Y. I. Role of folate in cancer development and progression. J. Nutrition. 2003; 133 (11); 3731-3739. |
| [18] | Boushey, C. J., Beresford, S. A., Omenn, G. S and Motulusky, A. G. A quantitative assessment of plasma homocysteine as a risk for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995; 274: 1049-1057. |
| [19] | Ebisch, I. M., Thomas, C. M., Peters, W. H., Braat, D. D and Steegers-Theunissen, R. P. the importance of folate, zinc and antioxidants in the pathogenesis and prevention of subfertility. Hum. Reprod Update. 2007; 13:163-174. |
| [20] | Mason, J. B. “A temporal association between folic acid fortifications and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis”. Cancer Epidemiol Biomarker Prev. 2007; 16 (7): 1325-1329. |
| [21] | Doshi, S. N., McDowell, I. F., Moat, S. J., Land, D., New Combe, K. G., Kredan, M. B. et al. Folate improves Endothelial function in coronary artery disease: an effect mediated by Reduction in intracellular superoxide. Arterioscler Thromb vasc Biol. 2001; 21: 196-1202. |
| [22] | Patrick, H. The Prevention of Memory Loss and Progression to Alzheimer’s Disease with B Vitamins, Antioxidants and Essential Fatty Acids: A Review of the Evidence. Available at http://www.foodforthebrain.org/media/229772/Holford.pdf. retrieved August 20th, 2015. |
| [23] | Bryan, J, Calvaresi, E and Hughes, D. Short term folate, vitamin B12 supplementation slightly affects memory performance but not mood of women in various ages. J. Nutr. 2002; 132, 1345-1356. |
| [24] | Gautam, N., Puligujja, P., Balkundi, S., Thakare, R., Liu, X., and Fox, H. et al. Pharmacokinetics, Biodistribution, and Toxicity of Folic Acid-Coated Antiretroviral Nanoformulations. Antimicrob Agents Chemother. 2014 Dec; 58 (12): 7510–7519. |
| [25] | Moreno-Cuerda, V. J, Morales-Conejo, M and Rubio, R “Antiretroviral treatment associated life-threatening adverse events”, Medicina clinica, 2006; 126 (19): 744-749. |
| [26] | http://emedicine.medscape.com/article/169814-overview retrieved August 20th, 2015. |
| [27] | http://www.medicinenet.com/carcinoembryonic_antigen/article.htm retrieved online on the 6th of August 2015. |
| [28] | Micali B, Florio MG, Venuti A, Artemisia A, Caputo G, Brancato U. Usefulness of carcinoembryonic antigen measurement in gastric juice of patients with gastric disorders. J Clin Gastroenterol. 1983; 5(5):411-5. |
| [29] | Bateman, A. C. and Hübscher, S. G. Cytokeratin expression as an aid to diagnosis in medical liver biopsies Histopathology 2010, Volume 56, Issue 4, pages 415–425. |
| [30] | Castelnuovo B, John L, Lutwama F, Ronald A, Spacek L. A, Bates M, et al. “Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity,” Journal of the International Association of Physicians in AIDS Care, 2009; vol. 8, no. 1, pp. 52–59. |
| [31] | M. Núñez, R. Lana, J. L. Mendoza, L. Martín-Carbonero, and V. Soriano, “Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy,” Journal of Acquired Immune Deficiency Syndromes,, 2001; vol. 27, no. 5, pp. 426–431. |
| [32] | Edwards, C. R. W., Bouchier, I. A. D., Haslett, C. and Chilvers, E. E. Diabetes Mellitus in Davidson’s Principle and Practice of Medicine (10th Edition). Churchhill Livingstone, London. 2008; 724–774. |
| [33] | Crook, M. A. Clinical Biochemistry and metabolic Medicine. 8TH ed. Edwaed Arnold publishers, London, 2012; 254-255. |
| [34] | http://telemedicine.itg.be/telemedicine/Uploads/ARLI_CME.pdf retrieved online on the 26/8/2015. |
APA Style
Aniekan Imo Peter, Gabriel Joseph Ekandem. (2015). Immunohistopathological Effects of Combined Administration of Douvir–N and Folc Acid on the Liver and Some Biochemical Parameters in Albino Wistar Rats. American Journal of BioScience, 3(6), 197-202. https://doi.org/10.11648/j.ajbio.20150306.11
ACS Style
Aniekan Imo Peter; Gabriel Joseph Ekandem. Immunohistopathological Effects of Combined Administration of Douvir–N and Folc Acid on the Liver and Some Biochemical Parameters in Albino Wistar Rats. Am. J. BioScience 2015, 3(6), 197-202. doi: 10.11648/j.ajbio.20150306.11
AMA Style
Aniekan Imo Peter, Gabriel Joseph Ekandem. Immunohistopathological Effects of Combined Administration of Douvir–N and Folc Acid on the Liver and Some Biochemical Parameters in Albino Wistar Rats. Am J BioScience. 2015;3(6):197-202. doi: 10.11648/j.ajbio.20150306.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajbio.20150306.11,
author = {Aniekan Imo Peter and Gabriel Joseph Ekandem},
title = {Immunohistopathological Effects of Combined Administration of Douvir–N and Folc Acid on the Liver and Some Biochemical Parameters in Albino Wistar Rats},
journal = {American Journal of BioScience},
volume = {3},
number = {6},
pages = {197-202},
doi = {10.11648/j.ajbio.20150306.11},
url = {https://doi.org/10.11648/j.ajbio.20150306.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbio.20150306.11},
abstract = {Douvir–N is a combination of lamivudine, zidovudine and nevirapine used for the treatment of patients with Human Immunodeficiency Virus. The objective of this study was to investigate the effect of combined administration of Douvir–N and folic acid on the histology and some Biochemical parameters in the liver of Wistar rats. Forty adult albino Wistar rats were randomly divided into four groups of ten animals each. Group A served as control and were administered with 1ml of distilled water, group B animals were administered with 9.29mg/kg body weight of Douvir–N, Group C animals were administered with a combination of 9.29mg/kg of Douvir–N and 0.07mg/kg of folic acid. Animals in group D were administered with 0.07mg/kg of folic acid. Animals were sacrificed after 30 days and dissected. The liver was removed and fixed in 10% buffered formaldehyde, processed and stained using Haematoxylin and Eosin staining method, carcino-embryonic antigen (CEA) and cytokeratin-7 (CK-7) immunochemistry methods. Stained slides were viewed using light microscope. Blood samples from each rat was collected using syringes and needles, The sera were extracted into fresh test tubes and stored in a refrigerator for analysis of aspartate aminotransaminase test (AST), alanine aminotransaminase test (ALT), alkaline phosphotase (ALP). The liver of Wistar rats administered with Douvir–N showed distortions in the liver with moderate dilatation of the sinusoidal spaces and nuclei pyknotic changes, with increased expression of CEA and CK7 in the groups treated with Douvir–N than the control groups. There was a significant increase in ALP in the Douvir–N groups. These changes were ameliorated when Douvir–N was combined with Folic acid. The findings suggest that Douvir–N can distort the cytoarchitecture and Biochemical parameters of the liver which could be ameliorated by co-administration with folic acid. Folic acid should be given as adjuvant drug to patients on Douvir–N therapy.},
year = {2015}
}
TY - JOUR T1 - Immunohistopathological Effects of Combined Administration of Douvir–N and Folc Acid on the Liver and Some Biochemical Parameters in Albino Wistar Rats AU - Aniekan Imo Peter AU - Gabriel Joseph Ekandem Y1 - 2015/09/26 PY - 2015 N1 - https://doi.org/10.11648/j.ajbio.20150306.11 DO - 10.11648/j.ajbio.20150306.11 T2 - American Journal of BioScience JF - American Journal of BioScience JO - American Journal of BioScience SP - 197 EP - 202 PB - Science Publishing Group SN - 2330-0167 UR - https://doi.org/10.11648/j.ajbio.20150306.11 AB - Douvir–N is a combination of lamivudine, zidovudine and nevirapine used for the treatment of patients with Human Immunodeficiency Virus. The objective of this study was to investigate the effect of combined administration of Douvir–N and folic acid on the histology and some Biochemical parameters in the liver of Wistar rats. Forty adult albino Wistar rats were randomly divided into four groups of ten animals each. Group A served as control and were administered with 1ml of distilled water, group B animals were administered with 9.29mg/kg body weight of Douvir–N, Group C animals were administered with a combination of 9.29mg/kg of Douvir–N and 0.07mg/kg of folic acid. Animals in group D were administered with 0.07mg/kg of folic acid. Animals were sacrificed after 30 days and dissected. The liver was removed and fixed in 10% buffered formaldehyde, processed and stained using Haematoxylin and Eosin staining method, carcino-embryonic antigen (CEA) and cytokeratin-7 (CK-7) immunochemistry methods. Stained slides were viewed using light microscope. Blood samples from each rat was collected using syringes and needles, The sera were extracted into fresh test tubes and stored in a refrigerator for analysis of aspartate aminotransaminase test (AST), alanine aminotransaminase test (ALT), alkaline phosphotase (ALP). The liver of Wistar rats administered with Douvir–N showed distortions in the liver with moderate dilatation of the sinusoidal spaces and nuclei pyknotic changes, with increased expression of CEA and CK7 in the groups treated with Douvir–N than the control groups. There was a significant increase in ALP in the Douvir–N groups. These changes were ameliorated when Douvir–N was combined with Folic acid. The findings suggest that Douvir–N can distort the cytoarchitecture and Biochemical parameters of the liver which could be ameliorated by co-administration with folic acid. Folic acid should be given as adjuvant drug to patients on Douvir–N therapy. VL - 3 IS - 6 ER -
Information
Email: